Table 2.
A comparison between CTLA-4 inhibitor monotherapy studies and the combination study of ipilimumab and nivolumab.
| Drug + target | Study (author, date) |
Patient number | Phase | Regimen + drugs (doses) | Response rate (%) (CR or PR) | Response duration | Drug related toxicity G3/4 AEs |
Treatment related mortality | PFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| Ipilimumab CTLA-4 |
Hodi et al., 2010 [12] Previously treated |
676 | 3 | Ipilimumab (3 mg/kg) versus ipilimumab + gp100 versus gp100 | 10.9 5.7 1.5 |
60% >26.5 months 17% >27.9 months 0% >2 years |
22.9% 17.4% 11.4% |
3.1% 2.1% 1.5% |
2.86 2.76 2.76 |
10.1 10.0 6.4 |
|
| ||||||||||
| Robert et al., 2011 [13] Previously untreated |
502 | 3 | Ipilimumab (10 mg/kg) + dacarbazine versus dacarbazine | 15.2 10.3 |
19.3 months (median) 8.1 months (median) |
56.3% 27.5% |
NR | <3 <3 |
11.2 9.1 |
|
|
| ||||||||||
| Lambrolizumab CTLA-4 |
Hamid et al., 2013 [14] | 655 | 1 | Lambrolizumab | 38 | 81% still responding at 11-month follow-up | 13% | NR | >7 | Not reached |
|
| ||||||||||
| Ipilimumab + nivolumab CTLA-4 + PD-1 |
Wolchok et al., 2013 [15] | 86 | 1 | Ipilimumab + nivolumab (concurrent or sequenced therapy) | 40a
20b |
90.5% of patients with a response had an ongoing response at time of analysis (6.1 to 72.1 weeks) | 53%a
18%b |
Nil Nil |
NR | NR |
aConcurrent therapy; bSequenced therapy; NR: not reported.